Skip to main content

Table 5 Estimates of key quantities characterizing the performance of the proposed two test workflow when 1-year or 3-year occurrences of hazardous events (HE) and clinical restenosis are taken into account

From: Stratification of coronary artery disease patients for revascularization procedure based on estimating adverse effects

Estimated quantity 1- year 3- years
Mean 95% CI Mean 95% CI
\( \widehat{P}\left(\mathrm{sBMS}\right) \) 5.6 3.4 – 9.8 6.4 3.1 – 13.0
\( \widehat{P}\left(\mathrm{sDES}\right) \) 85.5 81.9 – 87.6 84.1 78.4 – 87.2
\( \widehat{P}\left(\mathrm{sCABG}\right) \) 8.9 8.2 – 9.2 9.5 8.5 – 10.4
\( \widehat{P}\left(\mathrm{Restenosis}\left|\mathrm{sBMS}\right.\right) \) 0.0 0.0 – 0.0 0.0 0.0 – 0.0
\( \tilde{P}\left(\mathrm{Restenosis}\left|\mathrm{sDES}\right.\right) \) 2.9 1.9 – 3.4 8.2 7.6 – 9.0
\( \widehat{P}\left(\mathrm{Restenosis}\right) \) 2.7 1.8 – 3.1 7.1 6.4 – 7.9
\( \tilde{P}\left(\mathrm{Hazard}\left|\mathrm{sBMS}\right.\right) \) 7.2 0.0 – 16.1 9.9 0.0 – 21.4
\( \widehat{P}\left(\mathrm{Hazard}\left|\mathrm{sDES}\right.\right) \) 3.2 2.0 – 3.5 7.4 5.6 – 8.9
\( \widehat{P}\left(\mathrm{Hazard}\right) \) 3.9 2.7 – 4.6 7.6 6.2 – 8.9
Baseline estimate for P(Adverse effect) 9.7 8.4 – 10.3 19.7 18.2 – 20.7
Proposed estimate for P(Adverse effect) 6.5 5.0 – 7.6 14.7 13.1 – 16.1
ΔP(Adverse effect) 3.2 2.7 – 3.8 4.9 4.1 – 6.2
  1. The acronyms sBMS, sDES and sCABG denote that the proposed model suggested treatment with bare-metal stents, drug-eluting stents or coronary artery bypass grafting, respectively. Baseline refers to predominant treatment with drug-eluting stents as described in section “Baseline Effectiveness and Costs”.